Seven start-ups to go head-to-head at Femtech World Awards

Seven femtech start-ups have made the shortlist for Femtech World’s OB/GYN Innovation award sponsored by Cross-Border Impact Ventures. 

Cross–Border Impact Ventures is on a mission to revolutionise venture capital investing in health technology. The company invests in early-growth stage health technology companies commercialising medical devices, diagnostics, therapeutics and digital health innovations and leveraging cutting-edge technologies like AI and machine learning.

All financed innovations are relevant to women, children and adolescent health and located in North America, Europe and Israel with ability to scale technologies to Emerging Markets.

The shortlisted companies in the OB/GYN Innovation category stood out among some truly remarkable entries from all over the world.

The seven shortlisted entries will soon be judged by the category sponsor, with the ultimate winner announced at a virtual event on May 2.

Nesa Medtech is a a medical device start-up on a mission to transform women’s health by developing minimally invasive surgical solutions.

The company’s flagship product is a novel, minimally invasive and uterus-preserving technology aimed at treating uterine fibroids, a condition which has profound impacts on healthcare delivery and costs worldwide.

EndoCure aims to revolutionise the diagnosis of endometriosis with a novel robotic AI-powered ultrasound. The system is specifically designed to detect endometriosis lesions, which currently can’t be detected by imaging tools.

The ability to detect such lesions, EndoCure says, is crucial as the pain associated with endometriosis can be excruciating and life-altering. This capability not only promises to shorten the diagnostic journey for millions of women suffering from endometriosis but also aims to enhance the accuracy of diagnosis.

Hale offers a virtual-first care model that aims to reshape patient journeys for gynaecological conditions.

The platform leverages cutting-edge technology and interdisciplinary expertise to provide comprehensive care solutions, including online consultations, care navigation support, digital prescriptions and diagnostic fast-tracking processes.

Lasa Health is a health tech company supporting the diagnosis and management of pelvic pain disorders. The company uses AI and machine learning to screen patients for the potential causes of chronic pelvic pain.

Its algorithm, according to its developers, is able to catch conditions that would have otherwise been missed by physicians. The platform provides personalised recommendations for physicians to review and discuss with patients. 

Sonio is an AI solution for prenatal screening and diagnosis with over five years of research and collaborations between leading experts in foetal medicine and AI.

Sonio’s goal is to support foetal ultrasound practitioners in prenatal screening and diagnosis by assuring the completeness of their examination and increasing the accuracy of their patient scan results.

Based in Switzerland, Aspivix is a medical device company on a mission to reimagine and modernise gynaecology.

Its flagship product, Carevix, is the world’s first suction cervical stabiliser clinically proven to reduce pain and bleeding associated with transcervical procedures commonly performed in gynaecology, including IUD insertion, hysteroscopy, cervical biopsies and fertility treatments.

Yeda is developing a sustainable device that aims to support women’s pelvic floor and improve bladder control. The company is committed to improving women’s quality of life by offering personalised and user-friendly treatment.

Its device promises to disrupt the market by reducing hospital visits and providing gynaecologists with an innovative tool for their patients.